Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11084293 | 0.93 | ACP3 (0.53) | ALDH1A1L3MBTL1RAB9AKMT2AACP3 | |
| SCHEMBL8716433 | 0.82 | RAB9A (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27822368 | 0.80 | CA1 (0.42) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11089849 | 0.78 | CHRNA7 (0.38) | ALDH1A1TDP1TSHRMEN1KMT2A | |
| SCHEMBL11228132 | 0.75 | CA1 (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3389444 | 0.75 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5546047 | 0.74 | IDO1 (0.50) | TDP1TSHRMAPK1AOC3SMN1; SMN2 | |
| SCHEMBL5545227 | 0.74 | IDO1 (0.52) | ALDH1A1TSHRAOC3CYP1A2CYP2D6 | |
| SCHEMBL6447670 | 0.74 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL17616547 | 0.73 | ACP3 (0.49) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0362634-A2 | Basic dihydropyridines, process for their preparation and their use as intermediates | BAYER AG (DE) | 1990-04-11 | — | — | EP | claimed |
| EP-0046734-A2 | Aminohydroxyphenyl derivatives of cephalosporins, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1982-03-03 | — | — | EP | claimed |
| US-4288364-A | REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | claimed |
| US-4185014-A | Kentenimine intermediates for 6α-methoxy-α-carboxy penicillins | BEECHAM GROUP LIMITED (GB) | 1980-01-22 | — | — | US | claimed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | claimed |
| EP-2464623-B1 | THE RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8507673-B2 | Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds | EMORY UNIVERSITY (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| EP-2464623-A1 | THE RING OPENING OF LACTONES AND LACTAMS | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-20120041198-A1 | Process for Preparing 5,7 Diaminopyrazolo [1,5-a] Pyrimidine Compounds | EMORY UNIVERSITY | 2012-02-16 | — | — | US | disclosed |
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-4160837-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| EP-0000500-A2 | Cephalosprin derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-02-07 | — | — | EP | disclosed |
| US-4115566-A | 7α Ureido cephem-4-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4089955-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1978-05-16 | — | — | US | disclosed |
| US-4069324-A | CEPHALOSPORIN ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3996208-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
| US-3954802-A | Substituted-ureido derivatives of penam 3-carboxylic acid and cephem 4-carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041198-A1 | Process for Preparing 5,7 Diaminopyrazolo [1,5-a] Pyrimidine Compounds | DPYD, NUDT1, UMPS | CA1 3692/4885CA2 3969/4885CA12 4716/4885 |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | LSS, APH1A, OTUB1 | CA1 1473/4885CA2 3701/4885CA12 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.